General
Preferred name
DESLANOSIDE
Synonyms
Desacetyllanatoside C ()
Deacetyllanatoside C ()
Cedilanid-D ()
Deacetylanatoside c ()
Deslanosido ()
P&D ID
PD009820
CAS
17598-65-1
11004-41-4
Tags
available
drug
Approved by
FDA
Drug indication
Cardiovascular disease
Heart failure
Congestive cardiac insufficiency
Arrhythmia
Drug Status
approved
withdrawn
Max Phase
4.0
First approval
1982
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations [1][2][3].
DESCRIPTION Sodium/potassium-transporting ATPase inhibitor (pan). This compound was originally discovered in the leaves of Digitalis lanata, the woolly foxglove. (GtoPdb)
DESCRIPTION Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias associated with reentry mechanisms. It inhibits the Na-K-ATPase membrane pump, increasing intracellular sodium and calcium concentrations. (TargetMol Bioactive Compound Library)
Compound Sets
17
Cayman Chemical Bioactives
30872
ChEMBL Approved Drugs
CHEMBL1614
ChEMBL Drugs
CHEMBL1614
Drug Repurposing Hub
DrugBank
DB01078
DrugBank Approved Drugs
DB01078
DrugCentral
813
DrugCentral Approved Drugs
813
DrugMAP
DMB3ZSK
DrugMAP Approved Drugs
DMB3ZSK
Guide to Pharmacology
6806
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1614
MedChem Express Bioactive Compound Library
HY-A0154
NPC Screening Collection
Selleckchem Bioactive Compound Library
deslanoside
TargetMol Bioactive Compound Library
T8183
Withdrawn 2.0
150
External IDs
27
Properties
(calculated by RDKit )
Molecular Weight
942.48
Hydrogen Bond Acceptors
19
Hydrogen Bond Donors
9
Rotatable Bonds
10
Ring Count
9
Aromatic Ring Count
0
cLogP
0.04
TPSA
282.21
Fraction CSP3
0.94
Chiral centers
26.0
Largest ring
6.0
QED
0.1
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Drug Metabolite
Na+/K+ ATPase
Na+/K+-ATPase
ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2
ATPase
Indication
congestive heart failure, cardiac arrythmia
MOA
Na/K-ATPase inhibitor
ATC
C01AA07
Pathway
Membrane Transporter/Ion Channel
Metabolism
Metabolic Enzyme/Protease
Therapeutic Class
Antiarrhythmic Agents
Source data